Skip to main content

NF-κB Inhibitors for the Treatment of Inflammatory Diseases and Cancer

Buy Article:

$63.00 plus tax (Refund Policy)


The NF-κB/Rel signaling system is a paradigm for gene activation in response to inflammatory and menacing stimuli. Given the growing body of evidence showing an important involvement of NF-κB for the onset of autoimmune diseases and different types of cancer, NF-κB is an important drug target for the adjuvant therapy of these diseases. Great efforts have been made for the development of highly specific NF-κB inhibitors, some of them being currently tested in phase II clinical trials. Here we discuss recent progress in the identification of druggable components of the NF- κB signaling system and the development and potential use of novel NF-κB inhibitors.

Keywords: IKK; Inflammation; Inhibitor; IκB; NF-κB; Transcription factor; cancer

Document Type: Research Article


Affiliations: Institute of Biochemistry, Medical Faculty, Friedrichstrasse 24, Justus-Liebig-University, D-35392 Giessen Germany.

Publication date: February 1, 2007

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more